References
- Bowles DW, Weickhardt AJ, Doebele RC, et al (2012). Crizotinib for the treatment of patients with advanced non-small cell lung cancer. Drugs Today (Barc), 48, 271-82. https://doi.org/10.1358/dot.2012.48.4.1769835
- Cui L, Liu XX, Jiang Y, et al (2014). Phase II study on dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1699-702. https://doi.org/10.7314/APJCP.2014.15.4.1699
- Dai YM, Cui TJ, Liu ZH et al (2012). Human recombinant endostatin combined with cisplatin based chemotherapy in treating patients with NSCLC. J Clin Oncol, 17, 1036-9.
- Fei ZH, Yao CY, Yang XL,et al (2013). Serum BMP-2 upregulation as an indicator of poor survival in advanced non-small cell lung cancer patients. Asian Pac J Cancer Prev, 14, 5293-9. https://doi.org/10.7314/APJCP.2013.14.9.5293
- Fukuoka M, Wu YL, Thongprasert S, et al (2011). Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol, 29, 2866-74. https://doi.org/10.1200/JCO.2010.33.4235
- Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med, 359, 1367-80. https://doi.org/10.1056/NEJMra0802714
- Huang XE, Tian GY, Cao J, et al (2014). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7.
- Huang XE, Cao J, Qian ZY, et al (2014). Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia. Asian Pac J Cancer Prev, 15, 8495-7. https://doi.org/10.7314/APJCP.2014.15.19.8495
- Ji ZQ, Huang XE, Wu XY, et al (2014). Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients. Asian Pac J Cancer Prev, 15, 8603-5. https://doi.org/10.7314/APJCP.2014.15.20.8603
- Tian Y, Tang Z, We K, et al (2012). Meta analysis on Human recombinant endostatin combined with cisplatin based chemotherapy in treating patients with NSCLC. Chongqing Medical J, 37, 151-7.
- Welsh JW, Komaki R, Amini A, et a1 (2013). Phase 2 trial of erlotinib plus concurrent whole brain radiation therapy for patients with brain metastases from non-small-cell lung caneer. J Clin Oncol, 31, 895-902. https://doi.org/10.1200/JCO.2011.40.1174
- Wen L, Wang YS, Zhang CY et al(2013). Human recombinant endostatin administered in different time for SPC-A1. Chin Drug Clinic, 13, 21-2.
- Zhang Y, Liu PS (2013). Human recombinant endostatin combined with chemotherapy in treating 129 patients with NSCLC. Chin Social Physician, 15, 181-2.
Cited by
- Expression of Inhibitor of Differentiation-1 and Its Effects on Angiogenesis in Gastric Cancer vol.31, pp.7, 2016, https://doi.org/10.1089/cbr.2016.2043
- Assessing Tumor Response to Treatment in Patients with Lung Cancer Using Dynamic Contrast-Enhanced CT vol.6, pp.3, 2016, https://doi.org/10.3390/diagnostics6030028